Jazz Pharmaceuticals (FRA:J7Z) Beginning Cash Position: €1,601 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
74 GF Score
Price €213.40
GF Value €130.73
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Beginning Cash Position?

Jazz Pharmaceuticals FRA:J7Z +1.52% 74 Beginning Cash Position is €1,601 Mil as of Jun. 2026. GuruFocus rates FRA:J7Z with a GF Score™ of 74/100 and a GF Value™ of €130.73 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Jazz Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was €1,601 Mil.

Jazz Pharmaceuticals's quarterly Beginning Cash Position increased from Dec. 2025 (€1,132 Mil) to Mar. 2026 (€1,204 Mil) and increased from Mar. 2026 (€1,204 Mil) to Jun. 2026 (€1,601 Mil).

Jazz Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2023 (€808 Mil) to Dec. 2024 (€1,439 Mil) and increased from Dec. 2024 (€1,439 Mil) to Dec. 2025 (€2,061 Mil).

Jazz Pharmaceuticals Beginning Cash Position Related Terms

Jazz Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Beginning Cash Position Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 936.13 558.33 808.32 1,438.53 2,060.59

Jazz Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,614.27 1,013.77 1,132.46 1,203.99 1,600.85
FRA:J7Z
74GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €1,601 Mil mean?
Jazz Pharmaceuticals (FRA:J7Z) has a Beginning Cash Position of €1,601 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Beginning Cash Position too high?
Jazz Pharmaceuticals' current Beginning Cash Position is €1,601 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Beginning Cash Position compare to BBIO and ASND?
Jazz Pharmaceuticals' Beginning Cash Position of €1,601 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Beginning Cash Position is €1,601 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.73, compared to a current price of €213.40 — trading 63.2% above its estimated fair value. The current Beginning Cash Position is €1,601 Mil. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Beginning Cash Position is €1,601 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €213.40 is trading 63.2% above its estimated GF Value™ of €130.73. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • Beginning Cash Position: €1,601 Mil
  • GF Value™: €130.73 vs. price of €213.40 (63.2% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score

Get the complete analysis for FRA:J7Z

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€213.40
Price
€130.73
GF Value